NASDAQ:RETA - Reata Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $251.25
  • Forecasted Upside: 128.41 %
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$110.00
▼ -3.84 (-3.37%)
1 month | 3 months | 12 months
Get New Reata Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RETA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RETA

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$251.25
▲ +128.41% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Reata Pharmaceuticals in the last 3 months. The average price target is $251.25, with a high forecast of $348.00 and a low forecast of $220.00. The average price target represents a 128.41% upside from the last price of $110.00.
Buy
The current consensus among 6 contributing investment analysts is to buy stock in Reata Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/30/2019
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/28/2019
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/26/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/25/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/24/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/22/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/21/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/20/2021

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/25/2020Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellLower Price Target$260.00 ➝ $234.00Low
i
11/25/2020Smith Barney CitigroupLower Price Target$260.00 ➝ $234.00Low
i
11/10/2020Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellBoost Price Target$244.00 ➝ $260.00High
i
11/10/2020Cantor FitzgeraldBoost Price Target$169.00 ➝ $220.00High
i
11/10/2020Smith Barney CitigroupBoost Price Target$244.00 ➝ $260.00High
i
8/11/2020Cantor FitzgeraldLower Price Target$275.00 ➝ $169.00High
i
8/11/2020CitigroupLower Price TargetBuy$254.00 ➝ $244.00High
i
8/10/2020Stifel NicolausLower Price TargetBuy$280.00 ➝ $225.00Low
i
6/16/2020BTIG ResearchInitiated CoverageBuy$237.00Low
i
6/12/2020Robert W. BairdReiterated RatingBuy$268.00Low
i
Rating by Brian Skorney at Robert W. Baird
5/18/2020Cantor FitzgeraldBoost Price TargetOverweight$270.00 ➝ $275.00Medium
i
Rating by Charles Duncan at Cantor Fitzgerald
4/17/2020Jefferies Financial GroupBoost Price TargetBuy$335.00 ➝ $348.00Low
i
Rating by Maury Raycroft at Jefferies Financial Group Inc.
3/31/2020Stifel NicolausLower Price TargetBuy$362.00 ➝ $315.00High
i
Rating by Adam Walsh at Stifel Nicolaus
3/31/2020Robert W. BairdLower Price TargetOutperform$283.00 ➝ $268.00High
i
Rating by Brian Skorney at Robert W. Baird
3/31/2020CitigroupLower Price TargetBuy$328.00 ➝ $254.00High
i
Rating by Yigal Nochomovitz at Citigroup Inc.
2/20/2020Stifel NicolausBoost Price TargetBuy$305.00 ➝ $362.00Medium
i
Rating by Adam Walsh at Stifel Nicolaus
2/20/2020Robert W. BairdReiterated RatingOutperform$245.00 ➝ $283.00Low
i
Rating by Brian Skorney at Robert W. Baird
2/20/2020Cantor FitzgeraldReiterated RatingOverweight$314.00 ➝ $320.00High
i
Rating by Charles Duncan at Cantor Fitzgerald
2/18/2020Jefferies Financial GroupReiterated RatingBuy$308.00 ➝ $333.00Medium
i
Rating by Maury Raycroft at Jefferies Financial Group Inc.
11/27/2019Cantor FitzgeraldBoost Price Target$250.00 ➝ $314.00Low
i
Rating by Charles Duncan at Cantor Fitzgerald
11/20/2019Cantor FitzgeraldReiterated RatingOverweight$250.00 ➝ $314.00Medium
i
11/14/2019Stifel NicolausReiterated RatingPositive ➝ Buy$210.00 ➝ $305.00Low
i
11/13/2019National SecuritiesDowngradeBuy ➝ NeutralMedium
i
Rating by Maria Barbera at National Securities
11/12/2019CitigroupBoost Price TargetBuy$241.00 ➝ $328.00Medium
i
Rating by Yigal Nochomovitz at Citigroup Inc.
11/12/2019Robert W. BairdBoost Price TargetOutperform ➝ Positive$162.00 ➝ $245.00High
i
Rating by Brian Skorney at Robert W. Baird
11/4/2019Cantor FitzgeraldBoost Price TargetOverweight$180.00 ➝ $250.00Medium
i
10/16/2019LADENBURG THALM/SH SHReiterated RatingBuy ➝ Positive$133.00 ➝ $239.00High
i
10/16/2019Stifel NicolausBoost Price TargetBuy$135.00 ➝ $210.00High
i
10/15/2019SVB LeerinkSet Price TargetBuy$230.00Medium
i
Rating by Joseph Schwartz at SVB Leerink LLC
10/15/2019CitigroupBoost Price TargetBuy$194.00 ➝ $241.00High
i
Rating by Yigal Nochomovitz at Citigroup Inc.
10/15/2019Jefferies Financial GroupBoost Price TargetPositive ➝ Buy$128.00 ➝ $254.00High
i
10/15/2019Robert W. BairdReiterated RatingOutperform$105.00 ➝ $162.00High
i
10/15/2019Cantor FitzgeraldBoost Price TargetOverweight ➝ Overweight$125.00 ➝ $180.00High
i
10/14/2019SVB LeerinkBoost Price TargetOutperform$139.00 ➝ $180.00High
i
9/26/2019CitigroupReiterated RatingBuyHigh
i
Rating by Yigal Nochomovitz at Citigroup Inc.
9/26/2019National SecuritiesInitiated CoverageBuy$130.00Medium
i
8/8/2019CitigroupBoost Price TargetBuy$190.00 ➝ $194.00Medium
i
5/31/2019CitigroupBoost Price TargetBuy$185.00 ➝ $190.00Low
i
2/28/2019Cantor FitzgeraldReiterated RatingBuy$100.00High
i
Rating by Charles Duncan at Cantor Fitzgerald
2/20/2019Cantor FitzgeraldSet Price TargetBuy$100.00Low
i
Rating by Charles Duncan at Cantor Fitzgerald
11/7/2018Cantor FitzgeraldSet Price TargetBuy$100.00High
i
Rating by Charles Duncan at Cantor Fitzgerald
10/1/2018Cantor FitzgeraldReiterated RatingBuy$100.00High
i
Rating by C. Duncan at Cantor Fitzgerald
9/26/2018LADENBURG THALM/SH SHReiterated RatingBuy$133.00Low
i
Rating by Matthew Kaplan at LADENBURG THALM/SH SH
9/25/2018SVB LeerinkReiterated RatingOutperform ➝ Outperform$116.00 ➝ $139.00Medium
i
8/23/2018Cantor FitzgeraldInitiated CoverageOverweight$90.00Low
i
Rating by Charles Duncan at Cantor Fitzgerald
8/9/2018SVB LeerinkBoost Price TargetOutperform$64.00 ➝ $116.00Low
i
7/24/2018CitigroupBoost Price TargetBuy ➝ Buy$76.00 ➝ $95.00High
i
7/24/2018Robert W. BairdBoost Price TargetOutperform ➝ Outperform$47.00 ➝ $92.00High
i
4/9/2018CowenReiterated RatingHoldHigh
i
12/14/2017CowenReiterated RatingBuyMedium
i
11/14/2017CowenReiterated RatingBuyN/A
i
10/24/2017Robert W. BairdReiterated RatingBuy$47.00N/A
i
10/6/2017Jefferies Financial GroupReiterated RatingBuy$44.00N/A
i
9/13/2017SVB LeerinkInitiated CoverageOutperform ➝ Outperform$43.00Medium
i
Rating by J. Schwartz at SVB Leerink LLC
9/1/2017Robert W. BairdReiterated RatingBuy$47.00Medium
i
8/30/2017Jefferies Financial GroupInitiated CoverageBuy$44.00High
i
8/23/2017CitigroupReiterated RatingBuy$87.00 ➝ $78.00High
i
Rating by Yigal Nochomovitz at Citigroup Inc.
7/26/2017LADENBURG THALM/SH SHReiterated RatingBuy$55.00 ➝ $61.00High
i
Rating by Matthew Kaplan at LADENBURG THALM/SH SH
7/25/2017Robert W. BairdReiterated RatingOutperform$43.00 ➝ $47.00High
i
7/25/2017Stifel NicolausReiterated RatingBuy$38.00 ➝ $50.00High
i
Rating by Adam Walsh at Stifel Nicolaus
7/25/2017CitigroupReiterated RatingBuy ➝ Buy$39.00 ➝ $87.00High
i
Rating by Yigal Nochomovitz at Citigroup Inc.
7/24/2017Piper Jaffray CompaniesBoost Price TargetBuy$53.00 ➝ $60.00High
i
6/5/2017Piper Jaffray CompaniesReiterated RatingOverweight$48.00 ➝ $53.00High
i
5/9/2017CitigroupBoost Price TargetBuy$32.00 ➝ $39.00Low
i
4/13/2017LADENBURG THALM/SH SHInitiated CoverageBuy ➝ Buy$55.00Low
i
4/4/2017Piper Jaffray CompaniesReiterated RatingOverweight$48.00Medium
i
Rating by Charles Duncan at Piper Jaffray Companies
3/28/2017Piper Jaffray CompaniesReiterated RatingOverweight$48.00High
i
Rating by Charles Duncan at Piper Jaffray Companies
3/6/2017Piper Jaffray CompaniesReiterated RatingOverweight$48.00N/A
i
Rating by Charles Duncan at Piper Jaffray Companies
2/22/2017Stifel NicolausInitiated CoverageBuy ➝ Buy$38.00N/A
i
1/24/2017Robert W. BairdInitiated CoverageOutperform$43.00N/A
i
12/1/2016CowenReiterated RatingBuyN/A
i
10/7/2016Piper Jaffray CompaniesSet Price TargetBuy$33.00N/A
i
Rating by Charles Duncan at Piper Jaffray Companies
6/20/2016CitigroupInitiated CoverageBuy$32.00N/A
i
6/20/2016CowenInitiated CoverageOutperform$22.00N/A
i
6/20/2016Piper Jaffray CompaniesInitiated CoverageOverweight$33.00N/A
i
(Data available from 1/20/2016 forward)
Reata Pharmaceuticals logo
Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease(CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ataxia; and conduct phase 2 study for various form of CKD, such as IgA nephropathy, type 1 diabetic, and focal segmental glomerulosclerosis. It is also developing RTA 901, which completed Phase 1 clinical trials for the treatment of neurological diseases, such as diabetic neuropathy; and RORgT Inhibitors that are in the preclinical development phase for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases. In addition, the company offers bardoxolone for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD), as well as initiated phase 3 Falcon trial for the treatment of ADPKD. Further, it has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; and AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. Reata Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Plano, Texas.
Read More

Today's Range

Now: $110.00
$109.70
$115.82

50 Day Range

MA: $124.10
$111.93
$141.15

52 Week Range

Now: $110.00
$88.17
$257.96

Volume

299,666 shs

Average Volume

284,832 shs

Market Capitalization

$3.75 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.57

Frequently Asked Questions

What sell-side analysts currently cover shares of Reata Pharmaceuticals?

The following equities research analysts have issued research reports on Reata Pharmaceuticals in the last year: BTIG Research, Cantor Fitzgerald, Citigroup Inc., Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell, Jefferies Financial Group Inc., Robert W. Baird, Smith Barney Citigroup, and Stifel Nicolaus.

What is the current price target for Reata Pharmaceuticals?

8 Wall Street analysts have set twelve-month price targets for Reata Pharmaceuticals in the last year. Their average twelve-month price target is $251.25, suggesting a possible upside of 128.4%. Jefferies Financial Group Inc. has the highest price target set, predicting RETA will reach $348.00 in the next twelve months. Cantor Fitzgerald has the lowest price target set, forecasting a price of $220.00 for Reata Pharmaceuticals in the next year.

What is the current consensus analyst rating for Reata Pharmaceuticals?

Reata Pharmaceuticals currently has 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe RETA will outperform the market and that investors should add to their positions of Reata Pharmaceuticals.

What other companies compete with Reata Pharmaceuticals?

How do I contact Reata Pharmaceuticals' investor relations team?

Reata Pharmaceuticals' physical mailing address is 5320 LEGACY DRIVE, PLANO TX, 75024. The company's listed phone number is 972-865-2219 and its investor relations email address is ir@reatapharma.com. The official website for Reata Pharmaceuticals is www.reatapharma.com.